Macro Finance
Novartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion
Bloomberg Markets·October 2, 2026·1 min read
Novartis AG will license a messenger RNA-based autoimmune therapy from China's Abogen Biosciences in a deal worth up to $7.8 billion. The agreement gives Novartis global rights to the experimental treatment, expanding its presence in mRNA therapeutics beyond vaccines. Abogen receives upfront and milestone payments.
Read at Bloomberg MarketsDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.